Injectable GLP-1-based therapies, including semaglutide and tirzepatide, have demonstrated substantial benefits for weight loss and cardiometabolic risk reduction ( 1 3 ), but real-world uptake has been shaped by factors such as route of administration, access, tolerability, and insurance coverage ( 4 7 )
Most people begin noticing reduced appetite within the first 1-2 weeks of starting semaglutide
However, certain groups of people may be more likely to notice increased allergic rhinitis symptoms, including: People with a history of severe allergies If someone has strong allergic reactions to food, pollen, or medications, they may be more sensitive to changes caused by semaglutide
The standard is not that a substance must definitively enhance performance, but that it has the potential to do that